Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 12

Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives

Authors Zulfikar S, Mulholland S, Adamali H, Barratt SL

Received 11 March 2020

Accepted for publication 17 June 2020

Published 13 July 2020 Volume 2020:12 Pages 97—108

DOI https://doi.org/10.2147/CPAA.S228362

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Arthur Frankel


Sabrina Zulfikar, Sarah Mulholland, Huzaifa Adamali, Shaney L Barratt

Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK

Correspondence: Shaney L Barratt
Consultant Respiratory Physician and Honorary Associate Researcher, North Bristol NHS Trust, Southmead Hospital, Southmead, Bristol BS10 5NB, UK
Email Shaney.Barratt@nbt.nhs.uk

Abstract: Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this article, we will discuss the mechanisms of action, pre-clinical and clinical trial data surrounding inhibitors of the autotaxin-lysophosphatidic acid axis, which show promise as emerging novel therapies for fibrotic lung disease.

Keywords: autotaxin inhibitors, autotaxin-lysophosphatidic acid axis, idiopathic pulmonary fibrosis, interstitial lung disease, fibrotic lung disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]